Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

In terms of quality of life, someone 75 years old, retired with significant memory problems, can still have friends and, “a ...

The European Medicines Agency has granted restricted EU authorization to Eli Lilly’s Alzheimer’s drug Kisunla, reversing an ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...

Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

But now, after re-examining the drug at the request of Eli Lilly, the medicines committee has recommended granting Kisunla ...

A tiny flower-shaped particle could help to pave the way for a new treatment approach to Alzheimer's and Parkinson's that targets the root causes.

While more research is needed, including human trials, the results are promising. The drug SW033291 could lead to a new type ...

Without the receptor, ADGRG1, the microglia barely nibbled on the toxic protein. Using a mouse model of Alzheimer’s disease, the researchers observed how the loss of ADGRG1 led to the rapid buildup of ...